Literature DB >> 16079470

Activation of phosphoinositide 3-kinase, protein kinase C, and extracellular signal-regulated kinase is required for oridonin-enhanced phagocytosis of apoptotic bodies in human macrophage-like U937 cells.

Yan-Qiu Liu1, Song You, Shin-Ichi Tashiro, Satoshi Onodera, Takashi Ikejima.   

Abstract

Our previous study showed that oridonin isolated from Rabdosia rubescens enhanced phagocytosis of apoptotic cells by macrophage-like U937 cells through tumor necrosis factor (TNF) alpha and interleukin (IL)-1beta release. In this study, we further investigated signaling events involved in oridonin-augmented phagocytosis. Phagocytic stimulation was significantly suppressed by inhibitors, including a phosphoinositide 3-kinases (PI3K) inhibitor (wortmannin), a protein kinase C (PKC) inhibitor (stauroporine), and a phospholipase C (PLC) inhibitor (U73122). Exposure of U937 cells to oridonin caused an increase in PKC activity time- dependently, which was prevented by pretreatment with inhibitors of PI3K and PLC. Simultaneously, the activation of protein kinase B (PKB/Akt) and the increased expression of PLCgamma2 were also blocked by wortmannin. In addition, an extracellular signal-regulated kinase (ERK) MAPK inhibitor, PD98059, suppressed oridonin-augmented phagocytosis, whereas the p38 MAPK inhibitor (SB203580) and c-Jun N-terminal kinase (JNK) MAPK inhibitor (SP98059) had no inhibitory effect. Furthermore, pretreatment of U937 cells with anti-TNFalpha and anti-IL-1beta antibodies blocked oridonin-induced phagocytic stimulation as well as phosphorylation of ERK, but did not block the activation of PKC, indicating that these signaling events are triggered by oridonin, whereas secreted TNFalpha or IL-1beta only activate the ERK-dependent pathway. Taken together, oridonin is suggested to enhance phagocytosis of apoptotic bodies by activating PI3K, PKC, and ERK-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16079470     DOI: 10.1254/jphs.fpj05005x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  10 in total

1.  Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin.

Authors:  Angela M Wong; Yanjung Zhang; Kelly Kesler; Max Deng; Lucas Burhenn; David Wang; Aune Moro; Zhaoping Li; David Heber
Journal:  Exp Ther Med       Date:  2010-09-01       Impact factor: 2.447

2.  Foreign body-type multinucleated giant cell formation requires protein kinase C beta, delta, and zeta.

Authors:  Amy K McNally; Sarah R Macewan; James M Anderson
Journal:  Exp Mol Pathol       Date:  2007-11-09       Impact factor: 3.362

3.  Efficacy of rabdosia rubescens in the treatment of gingivitis.

Authors:  Sui Chen; Jiarong Liu; Handong Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11

Review 4.  Oridonin: targeting programmed cell death pathways as an anti-tumour agent.

Authors:  Z Liu; L Ouyang; H Peng; W-Z Zhang
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

Review 5.  Molecular Insight in the Multifunctional Effects of Oridonin.

Authors:  Brice Ayissi Owona; Herman J Schluesener
Journal:  Drugs R D       Date:  2015-09

6.  An Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages.

Authors:  Hye-Ran Kim; Hyun-Su Lee; Kyung-Sik Lee; In Duk Jung; Min-Sung Kwon; Chang-Hyun Kim; Seong-Min Kim; Myung-Han Yoon; Yeong-Min Park; Sang-Myeong Lee; Chang-Duk Jun
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

7.  Oridonin induces growth inhibition and apoptosis in human gastric carcinoma cells by enhancement of p53 expression and function.

Authors:  Enxu Bi; Dengqiang Liu; Youxi Li; Xuying Mao; Aihua Wang; Jingtao Wang
Journal:  Braz J Med Biol Res       Date:  2018-11-14       Impact factor: 2.590

8.  DNA damage induced by oridonin involves cell cycle arrest at G2/M phase in human MCF-7 cells.

Authors:  Tao Zhang; Yan Tan; Rui Zhao; Zhaoyang Liu
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15

9.  Cystatin F involvement in adenosine A2A receptor-mediated neuroinflammation in BV2 microglial cells.

Authors:  Wei Duan; Haoxiang Wang; Qinlin Fan; Lin Chen; Heqing Huang; Hong Ran
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

Review 10.  Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection.

Authors:  Jimin Xu; Eric A Wold; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Molecules       Date:  2018-02-22       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.